KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Operating Expenses: 2009-2025

Historic Operating Expenses for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to $316.9 million.

  • Ionis Pharmaceuticals' Operating Expenses rose 12.19% to $316.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 6.10%. This contributed to the annual value of $1.2 billion for FY2024, which is 3.40% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Operating Expenses of $316.9 million as of Q3 2025, which was up 1.50% from $312.2 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Operating Expenses peaked at $359.9 million during Q4 2022, and registered a low of $198.7 million during Q2 2021.
  • Moreover, its 3-year median value for Operating Expenses was $287.5 million (2023), whereas its average is $293.6 million.
  • In the last 5 years, Ionis Pharmaceuticals' Operating Expenses declined by 29.89% in 2021 and then skyrocketed by 64.04% in 2022.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Operating Expenses stood at $219.4 million in 2021, then skyrocketed by 64.04% to $359.9 million in 2022, then fell by 8.14% to $330.6 million in 2023, then increased by 2.05% to $337.4 million in 2024, then rose by 12.19% to $316.9 million in 2025.
  • Its Operating Expenses stands at $316.9 million for Q3 2025, versus $312.2 million for Q2 2025 and $278.5 million for Q1 2025.